Serveur d'exploration H2N2

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

How to overcome resistance of influenza A viruses against adamantane derivatives

Identifieur interne : 000081 ( PascalFrancis/Corpus ); précédent : 000080; suivant : 000082

How to overcome resistance of influenza A viruses against adamantane derivatives

Auteurs : C. Scholtissek ; G. Quack ; H. D. Klenk ; R. G. Webster

Source :

RBID : Pascal:98-0232689

Descripteurs français

English descriptors

Abstract

We tested two approaches to overcoming resistance of influenza A viruses against adamantane derivatives. First, adamantane derivatives that interfere with the ion channel function of the variant M2 protein of amantadine-resistant viruses may prevent drug resistance, if they are used in mixture with amantadine. Second, amantadine acts on the M2 protein (at low concentrations) and indirectly on the hemagglutinin (at concentrations at least 100 times higher). Identifying and using a drug that reacted with both targets at the same concentration might reduce development of resistance, since, in this case, two mutations, one in each target protein would be necessary at once. Such a double mutation is assumed to be a rare event. We evaluated forty adamantane derivatives and two related compounds to determine whether they interfered with plaque formation by influenza A strains, including A/Singapore/1/57 (H2N2). Variants resistant to drugs that interfered at low concentrations ( 1 μg/ml; e.g. amantadine) were cross-resistant with each other, but were sensitive to those agents effective at high concentrations (8 μg/ml; e.g. memantine). The former group of compounds act on the ion channel; the corresponding escape mutants tested had amino acid replacements at positions 27, 30 or 31 of the M2 protein. Hemagglutinin was the indirect target of the latter group of compounds. Variants resistant to these agents lacked amino acid replacements within the ion channel of the M2 protein and the mutants tested had amino acid replacements in the hemagglutinin. Although we failed to identify compounds that interacted with the ion channel of amantadine-resistant variants and inhibited their replication, we were able to construct at least two compounds that interfered with both the ion channel and the hemagglutinin at about the same concentration. After passage in the presence of these compounds, we either failed to obtain any drug-resistant mutants or those obtained had amino acid replacements in the ion channel of the M2 protein and the hemagglutinin.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0166-3542
A02 01      @0 ARSRDR
A03   1    @0 Antivir. res.
A05       @2 37
A06       @2 2
A08 01  1  ENG  @1 How to overcome resistance of influenza A viruses against adamantane derivatives
A11 01  1    @1 SCHOLTISSEK (C.)
A11 02  1    @1 QUACK (G.)
A11 03  1    @1 KLENK (H. D.)
A11 04  1    @1 WEBSTER (R. G.)
A14 01      @1 Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale @2 Memphis, TN 38101 @3 USA @Z 1 aut. @Z 4 aut.
A14 02      @1 Merz, GmbH, Eckenheimer Landstrasse 100-104 @2 60318 Frankfurt @3 DEU @Z 2 aut.
A14 03      @1 Institut für Virologie, Universität Marburg, Robert-Koch-Strasse 17 @2 35037 Marburg @3 DEU @Z 3 aut.
A20       @1 83-95
A21       @1 1998
A23 01      @0 ENG
A43 01      @1 INIST @2 18839 @5 354000075500810020
A44       @0 0000 @1 © 1998 INIST-CNRS. All rights reserved.
A45       @0 1 p./4
A47 01  1    @0 98-0232689
A60       @1 P
A61       @0 A
A64   1    @0 Antiviral research
A66 01      @0 NLD
C01 01    ENG  @0 We tested two approaches to overcoming resistance of influenza A viruses against adamantane derivatives. First, adamantane derivatives that interfere with the ion channel function of the variant M2 protein of amantadine-resistant viruses may prevent drug resistance, if they are used in mixture with amantadine. Second, amantadine acts on the M2 protein (at low concentrations) and indirectly on the hemagglutinin (at concentrations at least 100 times higher). Identifying and using a drug that reacted with both targets at the same concentration might reduce development of resistance, since, in this case, two mutations, one in each target protein would be necessary at once. Such a double mutation is assumed to be a rare event. We evaluated forty adamantane derivatives and two related compounds to determine whether they interfered with plaque formation by influenza A strains, including A/Singapore/1/57 (H2N2). Variants resistant to drugs that interfered at low concentrations ( 1 μg/ml; e.g. amantadine) were cross-resistant with each other, but were sensitive to those agents effective at high concentrations (8 μg/ml; e.g. memantine). The former group of compounds act on the ion channel; the corresponding escape mutants tested had amino acid replacements at positions 27, 30 or 31 of the M2 protein. Hemagglutinin was the indirect target of the latter group of compounds. Variants resistant to these agents lacked amino acid replacements within the ion channel of the M2 protein and the mutants tested had amino acid replacements in the hemagglutinin. Although we failed to identify compounds that interacted with the ion channel of amantadine-resistant variants and inhibited their replication, we were able to construct at least two compounds that interfered with both the ion channel and the hemagglutinin at about the same concentration. After passage in the presence of these compounds, we either failed to obtain any drug-resistant mutants or those obtained had amino acid replacements in the ion channel of the M2 protein and the hemagglutinin.
C02 01  X    @0 002B02S05
C03 01  X  FRE  @0 Influenzavirus A @2 NW @5 01
C03 01  X  ENG  @0 Influenzavirus A @2 NW @5 01
C03 01  X  SPA  @0 Influenzavirus A @2 NW @5 01
C03 02  X  FRE  @0 Antiviral @5 04
C03 02  X  ENG  @0 Antiviral @5 04
C03 02  X  SPA  @0 Antiviral @5 04
C03 03  X  FRE  @0 Résistance @5 07
C03 03  X  ENG  @0 Resistance @5 07
C03 03  X  SPA  @0 Resistencia @5 07
C03 04  X  FRE  @0 Amantadine @2 NK @2 FR @5 10
C03 04  X  ENG  @0 Amantadine @2 NK @2 FR @5 10
C03 04  X  SPA  @0 Amantadina @2 NK @2 FR @5 10
C03 05  X  FRE  @0 Mémantine @2 NK @2 FR @5 13
C03 05  X  ENG  @0 Memantine @2 NK @2 FR @5 13
C03 05  X  SPA  @0 Memantina @2 NK @2 FR @5 13
C03 06  X  FRE  @0 Canal ionique @5 16
C03 06  X  ENG  @0 Ionic channel @5 16
C03 06  X  SPA  @0 Canal iónico @5 16
C03 07  X  FRE  @0 Hémagglutinine @5 17
C03 07  X  ENG  @0 Hemagglutinin @5 17
C03 07  X  SPA  @0 Hemoaglutinina @5 17
C03 08  X  FRE  @0 Relation structure activité @5 18
C03 08  X  ENG  @0 Structure activity relation @5 18
C03 08  X  SPA  @0 Relación estructura actividad @5 18
C03 09  X  FRE  @0 Réversion @5 19
C03 09  X  ENG  @0 Reversion @5 19
C03 09  X  GER  @0 Reversion @5 19
C03 09  X  SPA  @0 Reversión @5 19
C03 10  X  FRE  @0 Protéine M2 @4 INC @5 86
C03 11  X  FRE  @0 Adamantane dérivé @4 INC @5 93
C07 01  X  FRE  @0 Orthomyxoviridae @2 NW
C07 01  X  ENG  @0 Orthomyxoviridae @2 NW
C07 01  X  SPA  @0 Orthomyxoviridae @2 NW
C07 02  X  FRE  @0 Virus @2 NW
C07 02  X  ENG  @0 Virus @2 NW
C07 02  X  SPA  @0 Virus @2 NW
N21       @1 153

Format Inist (serveur)

NO : PASCAL 98-0232689 INIST
ET : How to overcome resistance of influenza A viruses against adamantane derivatives
AU : SCHOLTISSEK (C.); QUACK (G.); KLENK (H. D.); WEBSTER (R. G.)
AF : Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale/Memphis, TN 38101/Etats-Unis (1 aut., 4 aut.); Merz, GmbH, Eckenheimer Landstrasse 100-104/60318 Frankfurt/Allemagne (2 aut.); Institut für Virologie, Universität Marburg, Robert-Koch-Strasse 17/35037 Marburg/Allemagne (3 aut.)
DT : Publication en série; Niveau analytique
SO : Antiviral research; ISSN 0166-3542; Coden ARSRDR; Pays-Bas; Da. 1998; Vol. 37; No. 2; Pp. 83-95; Bibl. 1 p./4
LA : Anglais
EA : We tested two approaches to overcoming resistance of influenza A viruses against adamantane derivatives. First, adamantane derivatives that interfere with the ion channel function of the variant M2 protein of amantadine-resistant viruses may prevent drug resistance, if they are used in mixture with amantadine. Second, amantadine acts on the M2 protein (at low concentrations) and indirectly on the hemagglutinin (at concentrations at least 100 times higher). Identifying and using a drug that reacted with both targets at the same concentration might reduce development of resistance, since, in this case, two mutations, one in each target protein would be necessary at once. Such a double mutation is assumed to be a rare event. We evaluated forty adamantane derivatives and two related compounds to determine whether they interfered with plaque formation by influenza A strains, including A/Singapore/1/57 (H2N2). Variants resistant to drugs that interfered at low concentrations ( 1 μg/ml; e.g. amantadine) were cross-resistant with each other, but were sensitive to those agents effective at high concentrations (8 μg/ml; e.g. memantine). The former group of compounds act on the ion channel; the corresponding escape mutants tested had amino acid replacements at positions 27, 30 or 31 of the M2 protein. Hemagglutinin was the indirect target of the latter group of compounds. Variants resistant to these agents lacked amino acid replacements within the ion channel of the M2 protein and the mutants tested had amino acid replacements in the hemagglutinin. Although we failed to identify compounds that interacted with the ion channel of amantadine-resistant variants and inhibited their replication, we were able to construct at least two compounds that interfered with both the ion channel and the hemagglutinin at about the same concentration. After passage in the presence of these compounds, we either failed to obtain any drug-resistant mutants or those obtained had amino acid replacements in the ion channel of the M2 protein and the hemagglutinin.
CC : 002B02S05
FD : Influenzavirus A; Antiviral; Résistance; Amantadine; Mémantine; Canal ionique; Hémagglutinine; Relation structure activité; Réversion; Protéine M2; Adamantane dérivé
FG : Orthomyxoviridae; Virus
ED : Influenzavirus A; Antiviral; Resistance; Amantadine; Memantine; Ionic channel; Hemagglutinin; Structure activity relation; Reversion
EG : Orthomyxoviridae; Virus
GD : Reversion
SD : Influenzavirus A; Antiviral; Resistencia; Amantadina; Memantina; Canal iónico; Hemoaglutinina; Relación estructura actividad; Reversión
LO : INIST-18839.354000075500810020
ID : 98-0232689

Links to Exploration step

Pascal:98-0232689

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">How to overcome resistance of influenza A viruses against adamantane derivatives</title>
<author>
<name sortKey="Scholtissek, C" sort="Scholtissek, C" uniqKey="Scholtissek C" first="C." last="Scholtissek">C. Scholtissek</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Quack, G" sort="Quack, G" uniqKey="Quack G" first="G." last="Quack">G. Quack</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Merz, GmbH, Eckenheimer Landstrasse 100-104</s1>
<s2>60318 Frankfurt</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Klenk, H D" sort="Klenk, H D" uniqKey="Klenk H" first="H. D." last="Klenk">H. D. Klenk</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Institut für Virologie, Universität Marburg, Robert-Koch-Strasse 17</s1>
<s2>35037 Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Webster, R G" sort="Webster, R G" uniqKey="Webster R" first="R. G." last="Webster">R. G. Webster</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">98-0232689</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0232689 INIST</idno>
<idno type="RBID">Pascal:98-0232689</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000081</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">How to overcome resistance of influenza A viruses against adamantane derivatives</title>
<author>
<name sortKey="Scholtissek, C" sort="Scholtissek, C" uniqKey="Scholtissek C" first="C." last="Scholtissek">C. Scholtissek</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Quack, G" sort="Quack, G" uniqKey="Quack G" first="G." last="Quack">G. Quack</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Merz, GmbH, Eckenheimer Landstrasse 100-104</s1>
<s2>60318 Frankfurt</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Klenk, H D" sort="Klenk, H D" uniqKey="Klenk H" first="H. D." last="Klenk">H. D. Klenk</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Institut für Virologie, Universität Marburg, Robert-Koch-Strasse 17</s1>
<s2>35037 Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Webster, R G" sort="Webster, R G" uniqKey="Webster R" first="R. G." last="Webster">R. G. Webster</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint>
<date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amantadine</term>
<term>Antiviral</term>
<term>Hemagglutinin</term>
<term>Influenzavirus A</term>
<term>Ionic channel</term>
<term>Memantine</term>
<term>Resistance</term>
<term>Reversion</term>
<term>Structure activity relation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Influenzavirus A</term>
<term>Antiviral</term>
<term>Résistance</term>
<term>Amantadine</term>
<term>Mémantine</term>
<term>Canal ionique</term>
<term>Hémagglutinine</term>
<term>Relation structure activité</term>
<term>Réversion</term>
<term>Protéine M2</term>
<term>Adamantane dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We tested two approaches to overcoming resistance of influenza A viruses against adamantane derivatives. First, adamantane derivatives that interfere with the ion channel function of the variant M2 protein of amantadine-resistant viruses may prevent drug resistance, if they are used in mixture with amantadine. Second, amantadine acts on the M2 protein (at low concentrations) and indirectly on the hemagglutinin (at concentrations at least 100 times higher). Identifying and using a drug that reacted with both targets at the same concentration might reduce development of resistance, since, in this case, two mutations, one in each target protein would be necessary at once. Such a double mutation is assumed to be a rare event. We evaluated forty adamantane derivatives and two related compounds to determine whether they interfered with plaque formation by influenza A strains, including A/Singapore/1/57 (H2N2). Variants resistant to drugs that interfered at low concentrations ( 1 μg/ml; e.g. amantadine) were cross-resistant with each other, but were sensitive to those agents effective at high concentrations (8 μg/ml; e.g. memantine). The former group of compounds act on the ion channel; the corresponding escape mutants tested had amino acid replacements at positions 27, 30 or 31 of the M2 protein. Hemagglutinin was the indirect target of the latter group of compounds. Variants resistant to these agents lacked amino acid replacements within the ion channel of the M2 protein and the mutants tested had amino acid replacements in the hemagglutinin. Although we failed to identify compounds that interacted with the ion channel of amantadine-resistant variants and inhibited their replication, we were able to construct at least two compounds that interfered with both the ion channel and the hemagglutinin at about the same concentration. After passage in the presence of these compounds, we either failed to obtain any drug-resistant mutants or those obtained had amino acid replacements in the ion channel of the M2 protein and the hemagglutinin.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0166-3542</s0>
</fA01>
<fA02 i1="01">
<s0>ARSRDR</s0>
</fA02>
<fA03 i2="1">
<s0>Antivir. res.</s0>
</fA03>
<fA05>
<s2>37</s2>
</fA05>
<fA06>
<s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>How to overcome resistance of influenza A viruses against adamantane derivatives</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>SCHOLTISSEK (C.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>QUACK (G.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>KLENK (H. D.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>WEBSTER (R. G.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale</s1>
<s2>Memphis, TN 38101</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Merz, GmbH, Eckenheimer Landstrasse 100-104</s1>
<s2>60318 Frankfurt</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Institut für Virologie, Universität Marburg, Robert-Koch-Strasse 17</s1>
<s2>35037 Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20>
<s1>83-95</s1>
</fA20>
<fA21>
<s1>1998</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>18839</s2>
<s5>354000075500810020</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>1 p./4</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>98-0232689</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i2="1">
<s0>Antiviral research</s0>
</fA64>
<fA66 i1="01">
<s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>We tested two approaches to overcoming resistance of influenza A viruses against adamantane derivatives. First, adamantane derivatives that interfere with the ion channel function of the variant M2 protein of amantadine-resistant viruses may prevent drug resistance, if they are used in mixture with amantadine. Second, amantadine acts on the M2 protein (at low concentrations) and indirectly on the hemagglutinin (at concentrations at least 100 times higher). Identifying and using a drug that reacted with both targets at the same concentration might reduce development of resistance, since, in this case, two mutations, one in each target protein would be necessary at once. Such a double mutation is assumed to be a rare event. We evaluated forty adamantane derivatives and two related compounds to determine whether they interfered with plaque formation by influenza A strains, including A/Singapore/1/57 (H2N2). Variants resistant to drugs that interfered at low concentrations ( 1 μg/ml; e.g. amantadine) were cross-resistant with each other, but were sensitive to those agents effective at high concentrations (8 μg/ml; e.g. memantine). The former group of compounds act on the ion channel; the corresponding escape mutants tested had amino acid replacements at positions 27, 30 or 31 of the M2 protein. Hemagglutinin was the indirect target of the latter group of compounds. Variants resistant to these agents lacked amino acid replacements within the ion channel of the M2 protein and the mutants tested had amino acid replacements in the hemagglutinin. Although we failed to identify compounds that interacted with the ion channel of amantadine-resistant variants and inhibited their replication, we were able to construct at least two compounds that interfered with both the ion channel and the hemagglutinin at about the same concentration. After passage in the presence of these compounds, we either failed to obtain any drug-resistant mutants or those obtained had amino acid replacements in the ion channel of the M2 protein and the hemagglutinin.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Influenzavirus A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Influenzavirus A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Influenzavirus A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Résistance</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Resistance</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Resistencia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Amantadina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Mémantine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Memantine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Memantina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Canal ionique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Ionic channel</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Canal iónico</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Hémagglutinine</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Hemagglutinin</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Hemoaglutinina</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Relation structure activité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Structure activity relation</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Relación estructura actividad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Réversion</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Reversion</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="GER">
<s0>Reversion</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Reversión</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Protéine M2</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Adamantane dérivé</s0>
<s4>INC</s4>
<s5>93</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21>
<s1>153</s1>
</fN21>
</pA>
</standard>
<server>
<NO>PASCAL 98-0232689 INIST</NO>
<ET>How to overcome resistance of influenza A viruses against adamantane derivatives</ET>
<AU>SCHOLTISSEK (C.); QUACK (G.); KLENK (H. D.); WEBSTER (R. G.)</AU>
<AF>Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale/Memphis, TN 38101/Etats-Unis (1 aut., 4 aut.); Merz, GmbH, Eckenheimer Landstrasse 100-104/60318 Frankfurt/Allemagne (2 aut.); Institut für Virologie, Universität Marburg, Robert-Koch-Strasse 17/35037 Marburg/Allemagne (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Antiviral research; ISSN 0166-3542; Coden ARSRDR; Pays-Bas; Da. 1998; Vol. 37; No. 2; Pp. 83-95; Bibl. 1 p./4</SO>
<LA>Anglais</LA>
<EA>We tested two approaches to overcoming resistance of influenza A viruses against adamantane derivatives. First, adamantane derivatives that interfere with the ion channel function of the variant M2 protein of amantadine-resistant viruses may prevent drug resistance, if they are used in mixture with amantadine. Second, amantadine acts on the M2 protein (at low concentrations) and indirectly on the hemagglutinin (at concentrations at least 100 times higher). Identifying and using a drug that reacted with both targets at the same concentration might reduce development of resistance, since, in this case, two mutations, one in each target protein would be necessary at once. Such a double mutation is assumed to be a rare event. We evaluated forty adamantane derivatives and two related compounds to determine whether they interfered with plaque formation by influenza A strains, including A/Singapore/1/57 (H2N2). Variants resistant to drugs that interfered at low concentrations ( 1 μg/ml; e.g. amantadine) were cross-resistant with each other, but were sensitive to those agents effective at high concentrations (8 μg/ml; e.g. memantine). The former group of compounds act on the ion channel; the corresponding escape mutants tested had amino acid replacements at positions 27, 30 or 31 of the M2 protein. Hemagglutinin was the indirect target of the latter group of compounds. Variants resistant to these agents lacked amino acid replacements within the ion channel of the M2 protein and the mutants tested had amino acid replacements in the hemagglutinin. Although we failed to identify compounds that interacted with the ion channel of amantadine-resistant variants and inhibited their replication, we were able to construct at least two compounds that interfered with both the ion channel and the hemagglutinin at about the same concentration. After passage in the presence of these compounds, we either failed to obtain any drug-resistant mutants or those obtained had amino acid replacements in the ion channel of the M2 protein and the hemagglutinin.</EA>
<CC>002B02S05</CC>
<FD>Influenzavirus A; Antiviral; Résistance; Amantadine; Mémantine; Canal ionique; Hémagglutinine; Relation structure activité; Réversion; Protéine M2; Adamantane dérivé</FD>
<FG>Orthomyxoviridae; Virus</FG>
<ED>Influenzavirus A; Antiviral; Resistance; Amantadine; Memantine; Ionic channel; Hemagglutinin; Structure activity relation; Reversion</ED>
<EG>Orthomyxoviridae; Virus</EG>
<GD>Reversion</GD>
<SD>Influenzavirus A; Antiviral; Resistencia; Amantadina; Memantina; Canal iónico; Hemoaglutinina; Relación estructura actividad; Reversión</SD>
<LO>INIST-18839.354000075500810020</LO>
<ID>98-0232689</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000081 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000081 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:98-0232689
   |texte=   How to overcome resistance of influenza A viruses against adamantane derivatives
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021